William J Chase bought $1.0M of Intellia Therapeutics (NTLA)
Executed Aug 20 2025, disclosed Aug 22 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 22 2025), the stock returned +68.7% (delay-adjusted); from the execution session (Aug 20 2025), +57.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
William J Chase (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Intellia Therapeutics, Inc. (NTLA). Across 1 priced purchase filing, the average 21-session return was +57.5% from execution and +68.7% from disclosure (delay-adjusted; derived). The largest single filing was $1.0M of NTLA (100,000 sh × $10.03, as filed), executed Aug 20 2025.
Healthcare · Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics usi…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→